We are currently not shipping Benlysta.
Information about Benlysta (Belimumab)
Benlysta (Belimumab) is used to treat systemic lupus erythematosus (SLE), a chronic autoimmune disease where the body’s immune system attacks its own tissues. It is typically prescribed for patients who have active SLE despite receiving standard treatments, and it helps to reduce disease activity and improve quality of life.
Benlysta is a monoclonal antibody that specifically targets and inhibits B-lymphocyte stimulator (BLyS). BLyS is a protein that supports the survival and proliferation of B cells, which are involved in the autoimmune processes of systemic lupus erythematosus (SLE). By inhibiting BLyS, Benlysta helps reduce the number of abnormal B cells contributing to the disease.
Product Highlights
- Part of medicine class benlysta is a monoclonal antibody.
- Specifically for patients with active SLE despite standard treatment, including those who are not achieving adequate control of their symptoms with conventional therapies.
- It is available as an intravenous infusion or a subcutaneous injection.
Key Ingredient
Key Benefits
- Helps in controlling disease symptoms and flares.
- Targets and inhibits the activity of B-lymphocyte stimulator (BLyS), a protein involved in the survival of B cells that contribute to autoimmune activity.
- Can enhance the overall quality of life for patients by reducing disease severity.
Directions for Use
- Intravenous Infusion: Administered by a healthcare professional, typically over a period of 1 hour. The initial dosing is usually every 2 weeks for the first 3 doses, followed by every 4 weeks.
- Subcutaneous Injection: Patients or caregivers can administer this form after proper training. The typical dosage is one injection once a week.
Safety Concern
- Belimumab can increase the risk of infections due to its effects on the immune system.
- Possible reactions during or after infusion, including fever, chills, or rash.
- Rare cases of mood changes or depression have been reported.
Avoid Benlysta (Belimumab) If
- Individuals with a known history of severe allergic reactions to belimumab or any other component of the drug.
- Patients with active, severe infections should avoid Benlysta until the infection is controlled.
- Should be used with caution; consult with a healthcare provider as it may not be recommended during pregnancy or breastfeeding without careful consideration.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.
